213 related articles for article (PubMed ID: 34982509)
41. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages.
Satta S; Meng Z; Hernandez R; Cavallero S; Zhou T; Hsiai TK; Zhou C
Theranostics; 2022; 12(6):2639-2657. PubMed ID: 35401811
[No Abstract] [Full Text] [Related]
42. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
43. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
Front Immunol; 2021; 12():730766. PubMed ID: 34630410
[TBL] [Abstract][Full Text] [Related]
44. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
[TBL] [Abstract][Full Text] [Related]
46. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
Rowland R; Brandariz-Nuñez A
Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
[TBL] [Abstract][Full Text] [Related]
47. Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
Mahindra A; Tejeda G; Rossi M; Janha O; Herbert I; Morris C; Morgan DC; Beattie W; Montezano AC; Hudson B; Tobin AB; Bhella D; Touyz RM; Jamieson AG; Baillie GS; Blair CM
PLoS One; 2021; 16(11):e0260283. PubMed ID: 34793553
[TBL] [Abstract][Full Text] [Related]
48. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo.
Kayabolen A; Akcan U; Özturan D; Ulbegi-Polat H; Sahin GN; Pinarbasi-Degirmenci N; Bayraktar C; Soyler G; Sarayloo E; Nurtop E; Ozer B; Guney-Esken G; Barlas T; Yildirim IS; Dogan O; Karahuseyinoglu S; Lack NA; Kaya M; Albayrak C; Can F; Solaroglu I; Bagci-Onder T
Adv Sci (Weinh); 2022 Sep; 9(27):e2201294. PubMed ID: 35896894
[TBL] [Abstract][Full Text] [Related]
49. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
50. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants.
Zhang L; Dutta S; Xiong S; Chan M; Chan KK; Fan TM; Bailey KL; Lindeblad M; Cooper LM; Rong L; Gugliuzza AF; Shukla D; Procko E; Rehman J; Malik AB
Nat Chem Biol; 2022 Mar; 18(3):342-351. PubMed ID: 35046611
[TBL] [Abstract][Full Text] [Related]
51. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Chatterjee D; Tauzin A; Laumaea A; Gong SY; Bo Y; Guilbault A; Goyette G; Bourassa C; Gendron-Lepage G; Medjahed H; Richard J; Moreira S; Côté M; Finzi A
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062348
[TBL] [Abstract][Full Text] [Related]
52. Missense mutations in spike protein of SARS-CoV-2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor.
Mahmood TB; Hossan MI; Mahmud S; Shimu MSS; Alam MJ; Bhuyan MMR; Emran TB
Immun Inflamm Dis; 2022 Sep; 10(9):e683. PubMed ID: 36039645
[TBL] [Abstract][Full Text] [Related]
53. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
[TBL] [Abstract][Full Text] [Related]
54. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
Wang WJ; Chen Y; Su WC; Liu YY; Shen WJ; Chang WC; Huang ST; Lin CW; Wang YC; Yang CS; Hou MH; Chou YC; Wu YC; Wang SC; Hung MC
J Food Biochem; 2022 Oct; 46(10):e14354. PubMed ID: 35894128
[TBL] [Abstract][Full Text] [Related]
55. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
56. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
Sinha S; Tam B; Wang SM
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
[TBL] [Abstract][Full Text] [Related]
57. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
58. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
59. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
[TBL] [Abstract][Full Text] [Related]
60. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
